Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Bossley, A. Gupta, N. Ullman, S. Saglani, M. Bracken-King, L. Fleming, A. Bush (London, United Kingdom). Omalizumab in children with severe asthma (SA): Which parameters improve after a 16 week trial?. Eur Respir J 2010; 36: Suppl. 54, 2641

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab in severe uncontrolled asthma: two and a half year clinical experience Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Patients’ adherence to treatment: How does it changes in 1 year after finishing of the participation in trial? Source: Annual Congress 2013 –New treatments and old dilemmas in the clinical management of lung diseases Year: 2013 Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Efficacy of reslizumab in adults with severe eosinophilic asthma with =3 exacerbations in the previous year: analyses at weeks 16 and 52 of two placebo-controlled phase 3 trials Source: International Congress 2017 – Asthma epidemiology among children and adults: from biomarkers to ACOS Year: 2017 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Number needed to treat (NNT) to prevent one exacerbation per year with omalizumab (OMA) In children with inadequately controlled allergic (IgE-mediated) asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Omalizumab in severe asthma: real life study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks Source: Eur Respir J 2002; 20: Suppl. 38, 406s Year: 2002 Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4 Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003